title: Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.
abstract: We present an overview of a number of key clinical studies in infiltrating gliomas presented at the 2013 Society for Neuro-Oncology and World Federation of Neuro-Oncology joint meeting. This review focuses on efficacy results, including quality of life studies, from larger clinical trials in both high- and low-grade infiltrating gliomas.
authors: Rimas V
authors: RV
authors: Lukas
authors: Christina
authors: C
authors: Amidei
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D060787:Neoplasm Grading; D009462:Neurology / Q000639:trends*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide